Sign In
Buy QDEL
$13.60
+0.310 (+2.33%)
At Close: Jun 03, 2026
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
02:45pm, Wednesday, 03'rd Jun 2026
QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
07:12am, Tuesday, 02'nd Jun 2026
SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing matern
A Look at QuidelOrtho Corp (QDEL) After 6.0% Gain -- GF Value $37.21 vs Price $13.06
09:23pm, Thursday, 28'th May 2026
On May 28, 2026, QuidelOrtho Corp (QDEL) shares rose 6.0% today, bringing the current price to $13.06. Over the past year, the stock has experienced significant
When Blood Compatibility Becomes a Pregnancy Risk
09:18am, Thursday, 21'st May 2026
SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic dis
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
07:00am, Wednesday, 20'th May 2026
SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of it
Hantavirus outbreak: these 3 stocks are poised to rip higher
11:44pm, Monday, 11'th May 2026
The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
01:21pm, Wednesday, 06'th May 2026
QuidelOrtho posts a wider Q1 loss as revenues fell 10.5% year over year, with weakness in respiratory testing pressuring margins and cash flow.
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
05:31am, Wednesday, 06'th May 2026
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates
07:10pm, Tuesday, 05'th May 2026
QuidelOrtho (QDEL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.37. This compares to earnings of $0.74 per share a year ago.
QuidelOrtho Reports First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ―
Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline
11:06am, Tuesday, 28'th Apr 2026
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuidelOrtho Corp (QDEL) Shares Surge 6.1% -- What GF Score of 60 Tells Investors
06:22pm, Monday, 27'th Apr 2026
On April 27, 2026, QuidelOrtho Corp (QDEL) shares rose 6.1% today, currently trading at $12.29. The stock has experienced a volatile year, with a 52-week range
Understanding and Addressing Syphilis Trends - and What's Being Missed
09:32am, Thursday, 23'rd Apr 2026
SAN DIEGO, April 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving sy
United Health Products (OTCMKTS:UEEC) and QuidelOrtho (NASDAQ:QDEL) Financial Comparison
04:54am, Thursday, 23'rd Apr 2026
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and United Health Products (OTCMKTS:UEEC - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two
TTP Group Announces the Sale of LEX Diagnostics
07:56am, Monday, 20'th Apr 2026
CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based mole
